The effect of zoledronic acid treatment on the prevention of secondary new vertebral compression fractures following percutaneous vertebroplasty
Not Applicable
- Conditions
- Diseases of the musculo-skeletal system and connective tissue
- Registration Number
- KCT0003919
- Lead Sponsor
- The Catholic University of Korea, Daejeon St. Mary's Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
1)BMD: T score > -3.7
(2)PVP-treated patient for OVCF
(3) Patients who meet all of the above criteria will be defined as the high risk group of secondary new compressionl fracture.
Exclusion Criteria
(1) Pathologic fracture: metastatic vertebral fracture, benign or malignant tumor of vertebral body (ex: multiple myeloma)
(2) Spinal infection
(3) Previous spinal surgery
(4) Systemic disease result in osteoporosis (ex: Vitamin D deficiency, Diabetes Mellitus, previous paresis)
(5) Patients with multiple compression fracture
(6) Patients with atrial fibrillation
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method subsequent vertebral compression fracture after percutaneous vertebroplasty-treated osteoporotic vertebral compression fracture
- Secondary Outcome Measures
Name Time Method Visual Analogue Scale score after percutaneous vertebroplasty